Related Experiment Video
Updated: Aug 10, 2026
Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
Published on: May 17, 2019
High Expression of BTN3A3 Acts as an Independent Predictive Factor of Better Prognosis in Patients with Sarcomas
1Orthopedics Department, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, 030001, People's Republic of China.
Background:
Butyrophilin subfamily 3 member A3 (BTN3A3) may be used as a prognostic biomarker for various malignancies. However, there is little evidence on the role of BTN3A3 in sarcomas.
Methods:
Using data from the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO), we detected BTN3A3 in normal and sarcomas tissues. Then we further evaluated clinical relevance, prognostic significance, genetic alternations, DNA methylation, co-expression gene and correlations with immune infiltration of BTN3A3.
Results:
The results showed that BTN3A3 expression was higher in sarcoma tissues than in normal tissues. The expression of BTN3A3 was regulated by methylation and miRNA. Higher BTN3A3 expression was associated with a better prognosis of sarcomas than lower BTN3A3 expression. GSEA revealed that the JAK-STAT signaling pathway, cytokine-cytokine receptor interaction, NK cell-mediated cytotoxicity, T cell receptor signaling pathway, cell adhesion, and Toll-like receptor signaling were differentially enriched in patients with elevated BTN3A3 expression. The BTN3A3 expression were found to be positively correlated with immune infiltration, immune checkpoints. In the multivariate analysis, high BTN3A3 expression was found to be an independent risk factor for overall survival.
Conclusion:
In conclusion, increased BTN3A3 expression is a significant predictor of better prognosis in patients with sarcomas.
